Affiliation:
1. Department of Hematology Hôpital of Hematology Yerevan Armenia
2. Service de Médecine Interne and Inflammation‐Immunopathology‐Biotherapy Department (DHU i2B) Hôpital Saint‐Antoine Paris France
3. French Armenian research center Yerevan Armenia
4. Department of Hematology, Hôpital Saint‐Louis Assistance Publique des Hôpitaux de Paris (AP‐HP) Paris France
5. INSERM U944 Institut de Recherche Saint‐Louis (IRSL) and Université de Paris Paris France
Abstract
AbstractIntroductionMyelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal myeloid malignancies, characterized by bone marrow failure leading to cytopenias (and possible myeloproliferation for CMML) and a high propensity to evolve to Acute Myeloid Leukemia (AML).Objective and MethodsThe aim of our retrospective study was to evaluate the clinical and hematological features; the prevalence of MDS subtypes, R‐IPSS, and the outcome of 106 Armenian MDS/CMML patients diagnosed over the 2008–2020 period in a single Armenian Hematology center and compare them to French MDS patients included in the GFM registry.ResultsMedian age in the Armenian cohort was 64 years (range 19–84) and 55% were males. The main MDS subtypes were MDS‐MLD (29.2%) and MDS‐SLD (27.3%), the least frequent was del 5q (0.9%). By comparison, a higher prevalence of MDS‐MLD, MDS‐EB2, and MDS‐RS was found in the French cohort. Armenian patients’ cohort generally had poor access to standard MDS treatment and 42.3% of the patients were transfusion dependent. Overall survival, however, did not significantly differ between Armenian and French cohorts.ConclusionOur study stresses issues regarding epidemiology, access to diagnosis, difficulties of risk stratification, and access to treatment.
Subject
Hematology,General Medicine